The enzymes most directly responsible for killing cancer cells are caspases, a family of proteins that act as the body’s built-in demolition crew. Caspases dismantle cells from the inside by chopping up essential proteins, breaking down the cell’s structural skeleton, and fragmenting its DNA. This process, called apoptosis or programmed cell death, is one of the body’s primary defenses against cancer. When caspases fail to activate, damaged cells survive and multiply unchecked.
How Caspases Destroy Cancer Cells
Caspases exist inside nearly every cell in your body, but they sit in an inactive form called procaspases, essentially waiting for a signal to switch on. When a cell accumulates DNA damage, receives stress signals, or gets flagged by the immune system, a chain reaction begins. “Initiator” caspases (mainly caspase-8 and caspase-9) activate first, then trigger “executioner” caspases (caspase-3, caspase-6, and caspase-7) to do the actual killing.
Caspase-3 is the most important executioner. Once activated, it cleaves over 500 different proteins inside the cell. It destroys the proteins that hold DNA together, shreds the cell’s internal scaffolding, and sends “eat me” signals to the surface of the dying cell so immune cells can clean up the debris. The entire process takes just a few hours from activation to complete cell death. Unlike necrosis, where cells burst open and cause inflammation, caspase-driven death is clean and controlled.
Why Cancer Cells Resist This Process
Cancer cells are remarkably good at disabling this system. Many tumors produce high levels of proteins that block caspase activation, essentially jamming the self-destruct switch. One of the most common is a group called IAPs (inhibitors of apoptosis proteins), which physically bind to caspases and prevent them from working. The protein survivin, for example, is found in most human cancers but is virtually absent in healthy adult tissue.
Other cancers take a different approach. Some disable the gene for the p53 protein, which normally detects DNA damage and triggers caspase activation. Roughly half of all human cancers carry mutations in the p53 gene, making it the single most commonly mutated gene in cancer. Without functioning p53, cells with severe DNA damage never receive the signal to activate their caspases and die. They keep dividing instead, accumulating more mutations with each generation.
Some tumor cells also overproduce a protein called Bcl-2, which guards the mitochondria (the cell’s energy centers) from releasing the chemical signals that would activate caspase-9. This was first discovered in certain lymphomas and has since been found across many cancer types.
Granzyme B: The Immune System’s Weapon
Your immune system has its own cancer-killing enzyme that works alongside caspases. Natural killer cells and cytotoxic T cells carry a protein called granzyme B, which they inject directly into target cells through tiny pores made by another protein called perforin. Once inside, granzyme B activates the same caspase cascade the cell would normally trigger on its own, but it bypasses many of the blocks cancer cells put up.
Granzyme B can also kill cells through caspase-independent pathways, directly attacking mitochondria and triggering DNA fragmentation on its own. This makes it effective even against some cancer cells that have disabled parts of their caspase machinery. Immunotherapy treatments work in part by helping T cells reach tumors and deliver granzyme B more effectively.
Enzymes Used in Cancer Treatment
Beyond the body’s natural defenses, certain enzymes are used directly as cancer therapies. L-asparaginase has been a cornerstone of leukemia treatment for decades. It works by breaking down asparagine, an amino acid that certain leukemia cells cannot produce on their own. Healthy cells make their own asparagine and are unaffected, but leukemia cells that depend on the blood supply for it essentially starve.
Researchers have also developed drugs that reactivate caspases in cancer cells. One approach targets the IAP proteins that block caspase activity. These drugs, called SMAC mimetics, mimic a natural protein that normally counteracts IAPs, freeing caspases to do their work. Another strategy focuses on the Bcl-2 blockade. A drug targeting Bcl-2 has shown strong results in certain blood cancers by releasing the brake on mitochondrial signaling and allowing caspase-9 to activate.
A compound called PAC-1 has drawn attention for its ability to directly convert procaspase-3 into active caspase-3 inside tumor cells. Cancer cells often contain unusually high levels of procaspase-3 compared to normal cells, which means a drug that activates this enzyme could preferentially kill cancer cells while doing less harm to healthy tissue. This approach has moved into clinical trials.
Other Enzymes Involved in Cancer Cell Death
Caspases get the most attention, but several other enzymes contribute to cancer cell death through different mechanisms. Endonuclease G is released from mitochondria during cell stress and chops up DNA without needing caspases at all. AIF (apoptosis-inducing factor) works similarly, traveling from mitochondria to the nucleus to trigger DNA destruction through a caspase-independent route.
Cathepsins, normally confined to the cell’s recycling compartments called lysosomes, can spill into the cell’s interior when those compartments are damaged. Once free, cathepsins digest internal proteins and can trigger caspase activation or kill the cell directly. Some cancer therapies aim to destabilize lysosomes specifically in tumor cells to unleash this effect.
The body’s cancer defenses rely on multiple overlapping enzyme systems rather than a single magic bullet. Caspase-3 remains the central executioner in most cancer cell death, but the immune system’s granzyme B, mitochondrial enzymes, and therapeutic enzymes like L-asparaginase each play distinct roles. Cancer’s ability to survive often comes down to how many of these pathways it manages to shut down simultaneously.